ArticleThe Journal of infectious diseases2025
Safety, Immunogenicity, and Protective Efficacy in Rhesus Macaques of a Novel Recombinant Hemagglutinin Protein Measles Virus Vaccine.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Distinct Humoral Response Development to Measles Virus Across Vaccine Platforms.The Journal of infectious diseases · 2026Article
- Mumps Virus: Replication, Immune Response, and the Changing Landscape of Vaccine Effectiveness.Pathogens (Basel, Switzerland) · 2026Review
- Stabilized Full-Length Measles Fusion Protein Elicits Potent Immunity and Protection In Vivo.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMeasles-mumps-rubella (MMR) is an effective live virus vaccine against measles but can be poorly immunogenic in young infants and contraindicated for pregnant and immunocompromised persons.
methodsWe evaluated immunogenicity and protective efficacy of a novel recombinant dimeric measles virus hemagglutinin protein vaccine (rMeV) in rhesus macaques. Macaques (n = 4) in 4 experimental groups were injected at days 0 and 42 with (1) MMR/MMR; (2) rMeV/rMeV; (3) MMR/rMeV; or (4) phosphate-buffered saline (PBS)/PBS and challenged intratracheally with wild-type measles virus (MeV) 8-9 months later. Blood, nasopharyngeal (NP), bronchoalveolar lavage (BAL), bone marrow (BM), and lymph node (LN) samples were collected.
resultsAll macaques that received a MeV-containing vaccine developed MeV-specific binding and neutralizing antibody titers that were similar at 169 days postvaccination, regardless of experimental group. After challenge, all unvaccinated macaques had MeV detected in samples of blood, NP, BAL, BM, and LN, and 1 developed a rash. No vaccinated macaque developed a rash or had detectable MeV in peripheral blood mononuclear cells, BM, or NP cells. However, MeV and MeV RNA were detected in BAL samples in all experimental groups, with the most virus and longest detection in rMeV-vaccinated animals.
conclusionsImmunization with rMeV protected macaques from rash, viremia, and systemic virus spread. Therefore, rMeV is protective against MeV disease and a promising option for patients unable to receive or respond to MMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.